| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010986876 |
| P356 | DOI | 10.1038/363515A0 |
| P3181 | OpenCitations bibliographic resource ID | 3406302 |
| P698 | PubMed publication ID | 8379998 |
| P50 | author | Chantal Desmaze | Q51778071 |
| P2093 | author name string | G A Rouleau | |
| M Sanson | |||
| B Plougastel | |||
| M Lutchman | |||
| K Hoang-Xuan | |||
| S Demczuk | |||
| P Merel | |||
| C Marineau | |||
| J Zucman | |||
| P2860 | cites work | The structure and organization of the human heavy neurofilament subunit (NF-H) and the gene encoding it | Q24296688 |
| Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours | Q24298221 | ||
| Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase with homology to the cytoskeletal-associated proteins band 4.1, ezrin, and talin | Q24305083 | ||
| Moesin: a member of the protein 4.1-talin-ezrin family of proteins | Q24314954 | ||
| A CA repeat 30 – 70 KB downstream from the adenomatous polyposis coli (APC) gene | Q24627449 | ||
| Molecular cloning of protein 4.1, a major structural element of the human erythrocyte membrane skeleton | Q24627974 | ||
| Basic local alignment search tool | Q25938991 | ||
| Unidirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing | Q27860941 | ||
| cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1 | Q28261183 | ||
| Sequence and domain structure of talin | Q28302349 | ||
| A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity | Q30495392 | ||
| Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma | Q30502386 | ||
| Molecular genetic approach to human meningioma: loss of genes on chromosome 22 | Q30502412 | ||
| Isolation of anonymous, polymorphic DNA fragments from human chromosome 22q12-qter | Q33493313 | ||
| Use of restriction enzymes to detect potential gene sequences in mammalian DNA. | Q35079757 | ||
| Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma | Q39590706 | ||
| Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). | Q39600883 | ||
| Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis | Q40568914 | ||
| Mapping of human chromosome 22 with a panel of somatic cell hybrids | Q41688364 | ||
| Translation of the rat LINE bicistronic RNAs in vitro involves ribosomal reinitiation instead of frameshifting | Q41947056 | ||
| Loss of heterozygosity on the long arm of chromosome 22 in pheochromocytoma | Q44111571 | ||
| Epidemiology of acoustic neuromas. | Q50588329 | ||
| Loss of constitutional heterozygosity in colon carcinoma from patients with familial polyposis coli. | Q54754246 | ||
| A cytogenetic study of 53 human gliomas. | Q55485308 | ||
| Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17 | Q56439564 | ||
| Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene | Q57419153 | ||
| Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22 | Q59076230 | ||
| Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints | Q60035789 | ||
| Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors | Q60035790 | ||
| Parental origin of chromosome 22 loss in sporadic and NF2 neuromas | Q60035794 | ||
| Assessment of chromosome 22 anomalies in neurinomas by combined karyotype and RFLP analyses | Q60035795 | ||
| Molecular characterization of chromosome 22 deletions in schwannomas | Q67544709 | ||
| The gene encoding the large human neurofilament subunit (NF-H) maps to the q121-q131 region on human chromosome 22 | Q67970275 | ||
| Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis | Q69817287 | ||
| P433 | issue | 6429 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurofibromin 2 | Q410233 |
| P304 | page(s) | 515-21 | |
| P577 | publication date | 1993-06-10 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 | |
| P478 | volume | 363 |
| Q72131324 | A 163-bp deletion in the neurofibromatosis 2 (NF2) gene associated with variant phenotypes [corrected] |
| Q30408869 | A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene |
| Q35380714 | A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2 |
| Q34385144 | A clinical variant of neurofibromatosis type 1: familial spinal neurofibromatosis with a frameshift mutation in the NF1 gene |
| Q36255151 | A conserved functional domain of Drosophila coracle is required for localization at the septate junction and has membrane-organizing activity |
| Q30422020 | A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma. |
| Q54560172 | A dual involvement of the amino-terminal domain of ezrin in F- and G-actin binding. |
| Q60065212 | A gene for neurofibromatosis 2 |
| Q50516116 | A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. |
| Q34470090 | A molecular view on paranodal junctions of myelinated fibers. |
| Q30544702 | A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals |
| Q26830181 | A neuronal function of the tumor suppressor protein merlin |
| Q28201463 | A novel isoform of beta-spectrin II localizes to cerebellar Purkinje-cell bodies and interacts with neurofibromatosis type 2 gene product schwannomin |
| Q58543600 | A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas |
| Q30498623 | A systematic screen for dominant second-site modifiers of Merlin/NF2 phenotypes reveals an interaction with blistered/DSRF and scribbler |
| Q30464276 | AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas |
| Q71621815 | Abnormalities of chromosome 22 in pediatric meningiomas |
| Q53410647 | Absence of hSNF5/INI1 mutation in human lung cancer. |
| Q34142952 | Activation of p21-activated kinase 2 by human immunodeficiency virus type 1 Nef induces merlin phosphorylation |
| Q47208014 | Advances in meningioma genetics: novel therapeutic opportunities |
| Q34035897 | Advances in neurofibromatosis 2 (NF2): a workshop report |
| Q38128516 | Advances in the treatment of neurofibromatosis-associated tumours. |
| Q42732368 | Age associated increase in the prevalence of chromosome 22q loss of heterozygosity in histological subsets of benign meningioma |
| Q72635284 | All in the (cancer) family |
| Q34512501 | Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor |
| Q73226522 | Altered expression of the ERM proteins in lung adenocarcinoma |
| Q71607439 | Altered morphology of vegetative amoebae induced by increased expression of the Dictyostelium discoideum ras-related gene rap1 |
| Q40425025 | Altered structure and expression of RB1 gene and increased phosphorylation of pRb in human vestibular schwannomas |
| Q44526324 | An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth |
| Q57163869 | An overview of meningiomas |
| Q92505476 | An update on the CNS manifestations of neurofibromatosis type 2 |
| Q85096594 | Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization |
| Q60035771 | Analysis of mutations in theSCH gene in schwannomas |
| Q48613043 | Analysis of the NF2 gene in oligodendrogliomas and ependymomas |
| Q31812816 | Analysis of the human neurofibromatosis type 2 gene promoter and its expression |
| Q30498859 | Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma |
| Q55479705 | Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin. |
| Q47094943 | Anesthesia for a parturient with intraneural perineurioma: A case report |
| Q34479368 | Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway |
| Q28237050 | Antioncogenes and human cancer |
| Q30530827 | Asbestos and mesothelioma: genetic lessons from a tragedy |
| Q61137097 | Assembly and activation of the Hippo signalome by FAT1 tumor suppressor |
| Q47373764 | Assignment of more than one gene to the same chromosome band on metaphase cytogenetics |
| Q35028723 | Association between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas |
| Q80191318 | Atypical manifestation of neurofibromatosis type 2 in a boy |
| Q64256808 | Atypical teratoid rhabdoid tumor mimicking type II neurofibromatosis: A case report |
| Q30457595 | Auditory rehabilitation of patients with neurofibromatosis Type 2 by using cochlear implants |
| Q45131093 | BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours |
| Q24533435 | Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains |
| Q36233656 | Biochemical and molecular characterization of the chicken cysteine-rich protein, a developmentally regulated LIM-domain protein that is associated with the actin cytoskeleton |
| Q55479313 | Blindness, deafness, quadriparesis, and a retinal malformation: the ravages of neurofibromatosis 2. |
| Q35576526 | Brain tumours: classification and genes |
| Q28201701 | CD44: from adhesion molecules to signalling regulators |
| Q38713914 | CNS Tumors in Neurofibromatosis. |
| Q34116094 | Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas |
| Q92446819 | Case-Based Review: meningioma |
| Q42811008 | Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene |
| Q40584203 | Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration |
| Q60035769 | Characterization of several DNA polymorphic markers in the LIF gene region |
| Q47855858 | Characterization of the human NIPSNAP1 gene from 22q12: a member of a novel gene family |
| Q38838646 | Checkpoint inhibition in meningiomas |
| Q30364937 | Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. |
| Q35746432 | Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups |
| Q79172919 | Chromosome 22q alterations and expression of the NF2 gene product, merlin, in gastrointestinal stromal tumors |
| Q34077480 | Chromosome imbalances in familial gliomas detected by comparative genomic hybridization |
| Q30503427 | Clinical and genetic patterns of neurofibromatosis 1 and 2. |
| Q33869028 | Clinical aspects of neurofibromatosis 1. |
| Q30455901 | Clinicopathologic assay of 15 tumor resections in a family with neurofibromatosis type 2. |
| Q48092726 | Clonal origin of recurrent meningiomas |
| Q22253159 | Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins |
| Q31026243 | Cloning and characterization of a novel gene (C17orf25) from the deletion region on chromosome 17p13.3 in hepatocelular carcinoma |
| Q24328861 | Cloning and characterization of hdlg: the human homologue of the Drosophila discs large tumor suppressor binds to protein 4.1 |
| Q52940698 | Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. |
| Q64927814 | Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas. |
| Q48867876 | Comparative genomic hybridization and mutation analyses of sporadic schwannomas. |
| Q30477880 | Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas |
| Q34403463 | Complex chromosome 22 rearrangements in astrocytic tumors identified using microsatellite and chromosome 22 tile path array analysis |
| Q38040446 | Complex single gene disorders and epilepsy. |
| Q41139111 | Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas |
| Q34169437 | Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy |
| Q33269178 | Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus |
| Q28507503 | Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. |
| Q30470418 | Congenital central nervous system tumors |
| Q57266579 | Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2 |
| Q40388570 | Constitutional DNA-level aberrations in chromosome 22 in a patient with multiple meningiomas. |
| Q46575531 | Constitutional p53 mutations associated with brain tumors in young adults |
| Q50741619 | Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. |
| Q24316396 | Construction of a transcription map around the gene for ataxia telangiectasia: identification of at least four novel genes |
| Q36118464 | Contact-dependent inhibition of EGFR signaling by Nf2/Merlin |
| Q57172733 | Contemporary Molecular Biology of Sporadic Vestibular Schwannomas: A Systematic Review and Clinical Implications |
| Q30464280 | Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides. |
| Q33367108 | Control of leaf and chloroplast development by the Arabidopsis gene pale cress |
| Q85013011 | CpG island hypermethylation of the neurofibromatosis type 2 (NF2) gene is rare in sporadic vestibular schwannomas |
| Q89960148 | Critical roles of phosphoinositides and NF2 in Hippo pathway regulation |
| Q28246519 | Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization |
| Q55476342 | Cytogenetic study of 33 ependymomas. |
| Q40418811 | Cytogenetics and molecular genetics of human solid tumours |
| Q37943757 | Cytokinesis, ploidy and aneuploidy |
| Q28279298 | DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo |
| Q36632942 | De novo mutations in neurological and psychiatric disorders: effects, diagnosis and prevention |
| Q72523726 | Debrisoquine hydroxylase gene polymorphism in meningioma |
| Q58862158 | Deletions on chromosome 22 in sporadic meningioma |
| Q74617476 | Detection of gains and losses in 18 meningiomas by comparative genomic hybridization |
| Q41733256 | Detection of novel NF2 mutations by an RNA mismatch cleavage method |
| Q30501507 | Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. |
| Q54766315 | Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection. |
| Q36198617 | Diagnosis and treatment options for nerve sheath tumors |
| Q38680767 | Diagnostic Challenges in Meningioma |
| Q36673027 | Diagnostic and molecular pathology of meningiomas |
| Q30495374 | Diagnostic issues in a family with late onset type 2 neurofibromatosis |
| Q33906075 | Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns |
| Q30495358 | Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas |
| Q54573044 | Differential gene expression between human schwannoma and control Schwann cells. |
| Q30308834 | Direct analysis for familial adenomatous polyposis mutations |
| Q30494553 | Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin |
| Q41834097 | Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity |
| Q46123470 | Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma |
| Q37410761 | Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway |
| Q37950977 | Drosophila cancer models. |
| Q30530560 | Drosophila coracle, a member of the protein 4.1 superfamily, has essential structural functions in the septate junctions and developmental functions in embryonic and adult epithelial cells |
| Q24336494 | E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton |
| Q28594472 | EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition |
| Q24676652 | ERM (ezrin/radixin/moesin)-based molecular mechanism of microvillar breakdown at an early stage of apoptosis |
| Q36382880 | ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons |
| Q29619893 | ERM proteins and merlin: integrators at the cell cortex |
| Q46666836 | Early proactive management of vestibular schwannomas in neurofibromatosis type 2. |
| Q40599153 | Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. |
| Q57266930 | Eleven novel mutations in the NF2 tumour suppressor gene |
| Q37885731 | Emerging therapeutic targets in schwannomas and other merlin-deficient tumors |
| Q30474678 | ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma |
| Q35027888 | Etiology of syndromic and nonsyndromic sensorineural hearing loss |
| Q47620432 | Evaluation of NF2 and NF1 tumor suppressor genes in distinctive gastrointestinal nerve sheath tumors traditionally diagnosed as benign schwannomas: s study of 20 cases |
| Q36168966 | Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization |
| Q73271606 | Evidence for a cytoskeleton attachment domain at the N-terminus of the NF2 protein |
| Q58862180 | Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas |
| Q30301216 | Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas |
| Q42254419 | Evolution and origin of HRS, a protein interacting with Merlin, the Neurofibromatosis 2 gene product. |
| Q21283962 | Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene |
| Q38837993 | Exogenous miRNA-146a Enhances the Therapeutic Efficacy of Human Mesenchymal Stem Cells by Increasing Vascular Endothelial Growth Factor Secretion in the Ischemia/Reperfusion-Injured Heart. |
| Q42810844 | Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins |
| Q34319788 | Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma |
| Q28146121 | Expression of the neurofibromatosis type 2 gene in human tissues |
| Q46040901 | Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. |
| Q73109201 | Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas |
| Q36235486 | Ezrin NH2-terminal domain inhibits the cell extension activity of the COOH-terminal domain |
| Q42720142 | Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family |
| Q36268138 | Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells |
| Q24617964 | Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site |
| Q24676628 | Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2 |
| Q35819867 | Ezrin: a regulator of actin microfilaments in cell junctions of the rat testis |
| Q40431889 | E‐Cadherin as an Invasion Suppressor |
| Q51802485 | Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2. |
| Q37734248 | Familial Schwannomatosis: A Diagnostic Challenge |
| Q88371763 | Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease |
| Q34480137 | Familial neurogenic tumor syndromes |
| Q50519269 | Family with neurofibromatosis type 2 and autosomal dominant hearing loss: identification of carriers of the mutated NF2 gene. |
| Q30502716 | Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas |
| Q73661080 | Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas |
| Q40402300 | Frequent loss of chromosome arm 1p DNA in parathyroid adenomas |
| Q34145489 | Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations |
| Q33761772 | Functional annotation of proteome encoded by human chromosome 22. |
| Q28146122 | Functional interaction of Fas-associated phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-kappaB activation |
| Q50957360 | Functional role of glycosphingolipids in contact inhibition of growth in a human mammary epithelial cell line. |
| Q40738340 | Future treatment modalities for meningiomas: targeting of neurofibromatosis type 2 and Ras-regulated pathways. |
| Q38441711 | Gene expression, signal transduction pathways and functional networks associated with growth of sporadic vestibular schwannomas |
| Q72036202 | Gene linkage and genetic deafness |
| Q51721478 | Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma. |
| Q38398807 | Genetic Severity Score predicts clinical phenotype in NF2. |
| Q63987395 | Genetic and epigenetic alteration of theNF2gene in sporadic meningiomas |
| Q30471127 | Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas |
| Q34783505 | Genetic insights into familial cancers-- update and recent discoveries |
| Q38953562 | Genetic landscape of meningioma |
| Q34438119 | Genetic predisposition to cancer and familial cancer syndromes |
| Q30454537 | Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes |
| Q40549515 | Genetics of familial and non-familial skull base tumours |
| Q38676440 | Genomic landscape of high-grade meningiomas. |
| Q33480310 | Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas |
| Q90157416 | Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2 |
| Q42977347 | Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study |
| Q30495361 | Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations |
| Q30355805 | Geographic distribution of vestibular schwannomas in West Scotland between 2000-2015 |
| Q34384437 | Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients |
| Q30502813 | Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. |
| Q46089331 | Germline screening of the NF-2 gene in families with unilateral vestibular schwannoma |
| Q54408782 | Global Gene Expression Profiling and Tissue Microarray Reveal Novel Candidate Genes and Down-Regulation of the Tumor Suppressor Gene CAV1 in Sporadic Vestibular Schwannomas |
| Q33809716 | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. |
| Q30453465 | Global profiling in vestibular schwannomas shows critical deregulation of microRNAs and upregulation in those included in chromosomal region 14q32. |
| Q30481231 | Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells |
| Q34605101 | Hemorrhagic vestibular schwannoma: review of the literature. |
| Q33734828 | Hereditary endocrinopathies |
| Q47784783 | Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. |
| Q31655533 | Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. |
| Q33738528 | High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas |
| Q36645990 | High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma |
| Q53663420 | High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. |
| Q28269498 | Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer |
| Q38779591 | Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis. |
| Q42240973 | Hippo and rassf1a Pathways: A Growing Affair |
| Q38231786 | Hippo-YAP signaling pathway: A new paradigm for cancer therapy |
| Q36655595 | Histological classification and molecular genetics of meningiomas |
| Q39244903 | Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth |
| Q24323041 | Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae |
| Q35205744 | Hunting for the causes of meningioma--obesity is a suspect |
| Q24338893 | Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein |
| Q24291083 | Identification of EPI64, a TBC/rabGAP domain-containing microvillar protein that binds to the first PDZ domain of EBP50 and E3KARP |
| Q24320046 | Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1 |
| Q33933200 | Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line |
| Q28580310 | Identification of a novel protein tyrosine phosphatase with sequence homology to the cytoskeletal proteins of the band 4.1 family |
| Q24316708 | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin |
| Q46803239 | Identification of genetic aberrations on chromosome 22 outside the NF2 locus in schwannomatosis and neurofibromatosis type 2. |
| Q54522129 | Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2. |
| Q30495325 | Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation |
| Q48864661 | Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma |
| Q34316029 | Identification of the protein 4.1 binding interface on glycophorin C and p55, a homologue of the Drosophila discs-large tumor suppressor protein |
| Q46783663 | Identification of three neurofibromatosis type 2 (NF2) gene mutations in vestibular schwannomas |
| Q74082793 | Immunohistochemistry study of human vestibular nerve schwannoma differentiation |
| Q90133611 | Impact of Surgery on Long-Term Results of Hearing in Neurofibromatosis Type-2 Associated Vestibular Schwannomas |
| Q35111282 | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila |
| Q37880216 | Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation |
| Q44390105 | Incidence and mortality of neurofibromatosis: a total population study in Finland |
| Q30443355 | Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2. |
| Q37299488 | Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer |
| Q40534803 | Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe |
| Q42810938 | Inhibition of NF-kappaB activation by merlin |
| Q40235602 | Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin |
| Q37999071 | Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors. |
| Q42493873 | Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. |
| Q53902140 | Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin. |
| Q41236837 | Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization |
| Q39268078 | Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network |
| Q50486035 | Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). |
| Q34052313 | Intramedullary ependymomas: clinical presentation, surgical treatment strategies and prognosis |
| Q55475713 | Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. |
| Q28728224 | Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells |
| Q34056666 | Ionizing radiation and genetic risks. XII. The concept of "potential recoverability correction factor" (PRCF) and its use for predicting the risk of radiation-inducible genetic disease in human live births |
| Q40870720 | Isolation and characterization of human NBL4, a gene involved in the beta-catenin/tcf signaling pathway |
| Q24654170 | Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction |
| Q51099434 | Kibra and Merlin Activate the Hippo Pathway Spatially Distinct from and Independent of Expanded. |
| Q39444934 | LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. |
| Q45922601 | Lack of neurofibromatosis type 2 gene promoter methylation in sporadic vestibular schwannomas. |
| Q30489292 | Laminin is required for Schwann cell morphogenesis |
| Q84928442 | Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes |
| Q50131782 | Linking Extracellular Matrix Agrin to the Hippo Pathway in Liver Cancer and Beyond. |
| Q34302208 | Localisation of the human gene encoding the cytoskeletal protein talin to chromosome 9p |
| Q48895739 | Localization of a putative low-penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling-path genomic microarray |
| Q36483405 | Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing |
| Q90574395 | Long-Term Outcomes of Stereotactic Radiosurgery for Vestibular Schwannoma Associated with Neurofibromatosis Type 2 in Comparison to Sporadic Schwannoma |
| Q38807760 | Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration |
| Q30391370 | Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors |
| Q33561323 | Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. |
| Q35156079 | Loss of 1p and 7p in radiation-induced meningiomas identified by comparative genomic hybridization |
| Q37599488 | Loss of Merlin induces metabolomic adaptation that engages dependence on Hedgehog signaling |
| Q86924304 | Loss of NF2/Merlin expression in advanced sporadic colorectal cancer |
| Q30458195 | Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells |
| Q48458744 | Loss of chromosome 1 in myxopapillary ependymoma suggests a region out of chromosome 22 as critical for tumour biology: a FISH analysis of four cases on touch imprint smears |
| Q30493308 | Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2 |
| Q48871804 | Loss of heterozygosity on chromosome 22 in human gliomas does not inactivate the neurofibromatosis type 2 gene |
| Q30437229 | Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling |
| Q38791538 | Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer |
| Q40667179 | Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma |
| Q55360778 | Low incidence of a nucleotide sequence alteration of the neurofibromatosis 2 gene in human breast cancers. |
| Q64949275 | M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma. |
| Q34378971 | MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase |
| Q24306359 | Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2 |
| Q37843031 | Mammalian Hippo pathway: from development to cancer and beyond |
| Q36251326 | Management of the patient and family with neurofibromatosis 2: a consensus conference statement |
| Q48378152 | Meningioma of the cerebellopontine angle in identical twins: a case report |
| Q35769435 | Meningiomas |
| Q53372846 | Merlin and ERM proteins: unappreciated roles in cancer development? |
| Q35777641 | Merlin and the ERM proteins in Schwann cells, neurons and growth cones |
| Q34389516 | Merlin is a negative regulator of human melanoma growth |
| Q37422836 | Merlin is a potent inhibitor of glioma growth |
| Q30476110 | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis |
| Q48236413 | Merlin links to the cAMP neuronal signaling pathway by anchoring the RIbeta subunit of protein kinase A. |
| Q42833103 | Merlin neutralizes the inhibitory effect of Mdm2 on p53. |
| Q30373369 | Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury. |
| Q39069340 | Merlin sumoylation is required for its tumor suppressor activity |
| Q28283076 | Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival |
| Q38010858 | Merlin, a multi-suppressor from cell membrane to the nucleus |
| Q38105985 | Merlin, the NF2 gene product |
| Q30418770 | Merlin/ERM proteins establish cortical asymmetry and centrosome position |
| Q35880377 | Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. |
| Q57275662 | Merlin: hanging tumor suppression on the Rac |
| Q33600670 | Merlin: the neurofibromatosis 2 tumor suppressor |
| Q38023101 | Merlin: the wizard requires protein stability to function as a tumor suppressor |
| Q28510087 | Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors |
| Q30472662 | MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival |
| Q30456266 | Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation |
| Q56673183 | Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3 |
| Q24683906 | Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3 |
| Q30494424 | Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants |
| Q30495365 | Misleading linkage results in an NF2 presymptomatic test owing to mosaicism |
| Q36494071 | Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth |
| Q40474174 | Molecular Genetics of Exocrine Pancreatic Neoplasms |
| Q26739662 | Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling |
| Q30501205 | Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis |
| Q41626535 | Molecular aspects of neuro-oncology |
| Q28241993 | Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and polymorphisms in the NF1 gene |
| Q28286827 | Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor |
| Q22253995 | Molecular cloning of a novel NF2/ERM/4.1 superfamily gene, ehm2, that is expressed in high-metastatic K1735 murine melanoma cells |
| Q36235682 | Molecular dissection of radixin: distinct and interdependent functions of the amino- and carboxy-terminal domains |
| Q33643298 | Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer |
| Q24671002 | Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas |
| Q30495336 | Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. |
| Q30486859 | Molecular genetic aspects of human cancers: the 1993 Frank Rose Lecture |
| Q54656865 | Molecular genetics alterations and tumor behavior of sporadic vestibular schwannoma from the People's Republic of China. |
| Q24518449 | Molecular genetics of neurofibromatosis type 1 (NF1) |
| Q74736163 | Molecular genetics of renal cell carcinoma |
| Q38204110 | Molecular insights into NF2/Merlin tumor suppressor function |
| Q30457681 | Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms |
| Q36021567 | Molecular pathogenesis of meningiomas. |
| Q30495332 | Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas |
| Q49166967 | Mortality of neurofibromatosis in Japan, 1968-1992. |
| Q34244318 | Mouse models of neurofibromatosis |
| Q24682869 | Mouse models of neurofibromatosis 1 and 2. |
| Q72282554 | Multiple neurilemmoma in both legs. A case report |
| Q30492334 | Multiple schwannomas: report of two cases |
| Q73404283 | Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis? |
| Q40716873 | Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway |
| Q30502691 | Mutational analysis of patients with neurofibromatosis 2 |
| Q80287223 | Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings |
| Q54466787 | Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas. |
| Q48181670 | Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types |
| Q36273267 | NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition |
| Q35795458 | NF2 gene analysis distinguishes hemangiopericytoma from meningioma. |
| Q53423655 | NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. |
| Q73498442 | NF2 in monozygotic twins |
| Q48350627 | NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH. |
| Q55355075 | NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. |
| Q37275182 | NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth |
| Q35563136 | NF2: the wizardry of merlin |
| Q45092731 | NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer |
| Q28592252 | Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells |
| Q46902773 | Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways |
| Q38605389 | Neurocutaneous Syndromes and Brain Tumors |
| Q72146593 | Neurofibromatosis |
| Q95809990 | Neurofibromatosis 1 |
| Q34577777 | Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. |
| Q40830056 | Neurofibromatosis 1 in childhood |
| Q57266756 | Neurofibromatosis 2 (NF2) and Malignant Mesothelioma in a Man with a Constitutional NF2 Missense Mutation |
| Q37709703 | Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L |
| Q24319849 | Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling |
| Q37571402 | Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. |
| Q79448696 | Neurofibromatosis 2 leads to choroidal hyperfluorescence in fluorescein angiography |
| Q73627035 | Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas |
| Q39981215 | Neurofibromatosis 2 tumor suppressor, the gene induced by valproic acid, mediates neurite outgrowth through interaction with paxillin |
| Q24323104 | Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin |
| Q41099831 | Neurofibromatosis 2: loss of merlin's protective spell |
| Q30372453 | Neurofibromatosis Type 2 Presenting with Oculomotor Ophthalmoplegia and Distal Myopathy. |
| Q54191697 | Neurofibromatosis Type 2. |
| Q41176229 | Neurofibromatosis and associated tumour suppressor genes |
| Q28279834 | Neurofibromatosis type 1: piecing the puzzle together |
| Q24681430 | Neurofibromatosis type 2 |
| Q21202892 | Neurofibromatosis type 2 (NF2): a clinical and molecular review |
| Q40961524 | Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function |
| Q71787744 | Neurofibromatosis type 2 in an adolescent boy with polyneuropathy and a mutation in the NF2 gene |
| Q50459734 | Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom. |
| Q30498854 | Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton |
| Q55234046 | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. |
| Q30459213 | Neurofibromatosis type 2 tumor suppressor protein, NF2, induces proteasome-mediated degradation of JC virus T-antigen in human glioblastoma |
| Q80024257 | Neurofibromatosis type 2 with multiple plexiform schwannomas |
| Q30577142 | Neurofibromatosis type 2 with multiple primary brain tumors in monozygotic twins |
| Q30391375 | Neurofibromatosis type 2. |
| Q79908666 | Neurofibromatosis type 2: a case of ptosis |
| Q71690852 | Neurofibromatosis type 2: a new mechanism of tumor suppression |
| Q30355245 | Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis. |
| Q30449267 | Neurofibromatosis: chronological history and current issues |
| Q40479891 | Neuropathology and Molecular Genetics of Neurofibromatosis 2 and Related Tumors |
| Q36950751 | Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns. |
| Q41669132 | Neurovascular patterning cues and implications for central and peripheral neurological disease |
| Q28508442 | Normal development of mice and unimpaired cell adhesion/cell motility/actin-based cytoskeleton without compensatory up-regulation of ezrin or radixin in moesin gene knockout |
| Q40525111 | Not just glue: cell-cell junctions as cellular signaling centers |
| Q22010248 | Novel alternatively spliced isoforms of the neurofibromatosis type 2 tumor suppressor are targeted to the nucleus and cytoplasmic granules |
| Q34057634 | Ocular abnormalities in neurofibromatosis 2. |
| Q73429734 | On Arachnoid Villi and Meningiomas: Functional Implication of Ultrastructure, Cell Adhesion Mechanisms, and Extracellular Matrix Composition |
| Q41136186 | On the trail of the genetics and pathophysiology of schizophrenia |
| Q30398838 | Oncogenic role of Merlin/NF2 in glioblastoma |
| Q30438898 | Optimizing biologically targeted clinical trials for neurofibromatosis. |
| Q28277373 | Organizing the cell cortex: the role of ERM proteins |
| Q41705181 | Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling |
| Q48134379 | Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. |
| Q47144604 | Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation |
| Q39739259 | Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma |
| Q36762621 | PIKE GTPase are phosphoinositide-3-kinase enhancers, suppressing programmed cell death |
| Q104795147 | PLPP/CIN-mediated NF2-serine 10 dephosphorylation regulates F-actin stability and Mdm2 degradation in an activity-dependent manner |
| Q28572513 | Paranodin, a glycoprotein of neuronal paranodal membranes |
| Q57266478 | Pathogenesis and management of type 2 neurofibromatosis |
| Q41153201 | Pathology of meningiomas |
| Q44064233 | Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology |
| Q41136153 | Pediatric cancer: environmental and genetic aspects |
| Q48674799 | Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation |
| Q35939735 | Peripheral nerve tumors: management strategies and molecular insights |
| Q92572049 | Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival |
| Q90146619 | Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas |
| Q36119138 | Phosphorylation and activity of the tumor suppressor Merlin and the ERM protein Moesin are coordinately regulated by the Slik kinase |
| Q30488858 | Phosphorylation of merlin regulates its stability and tumor suppressive activity |
| Q42770445 | Phosphorylation of the growth arrest-specific protein Gas2 is coupled to actin rearrangements during Go-->G1 transition in NIH 3T3 cells |
| Q36445494 | Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity |
| Q42223215 | Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells |
| Q38673320 | Population rCharacteristics and Progressive Disability in Neuofibromatosis Type 2. |
| Q30459589 | Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas |
| Q37202827 | Predictors of the risk of mortality in neurofibromatosis 2 |
| Q57304749 | Predominant occurrence of somatic mutations of theNF2 gene in meningiomas and schwannomas |
| Q40425487 | Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations |
| Q36385447 | Primary intrasellar schwannoma: clinical, aetiopathological and surgical considerations |
| Q30495647 | Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma |
| Q50874321 | Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. |
| Q30873760 | Protective immunity against Taenia crassiceps murine cysticercosis induced by DNA vaccination with a Taenia saginata tegument antigen. |
| Q52044845 | Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. |
| Q46856638 | Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton |
| Q58114475 | Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas |
| Q34062012 | Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas |
| Q90250769 | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins |
| Q79432475 | Purification of the NF2 tumor suppressor protein from human erythrocytes |
| Q28730289 | Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis |
| Q41073081 | Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. |
| Q30450062 | Radiographic association of schwannomas with sensory ganglia |
| Q40764834 | Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. |
| Q34138129 | Recessive oncogenes: current status |
| Q52608306 | Reconstructing the molecular life history of gliomas. |
| Q35588092 | Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. |
| Q30486851 | Reduced expression of neurofibromin in human meningiomas |
| Q36634951 | Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. |
| Q24671083 | Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway |
| Q43732521 | Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. |
| Q92855451 | Regulation of TEAD Transcription Factors in Cancer Biology |
| Q48452472 | Regulation of the neurofibromatosis 2 gene promoter expression during embryonic development |
| Q42830999 | Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli |
| Q61449897 | Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females |
| Q38505467 | Relevance of cytogenetic and fluorescent in situ hybridization analyses in the clinical assessment of soft tissue sarcoma. |
| Q71670298 | Rhabdoid tumor of the kidney with primitive neuroectodermal tumor of the central nervous system: associated tumors with different histologic, cytogenetic, and molecular findings |
| Q24678197 | Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association |
| Q38610718 | RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts |
| Q36189820 | Role of Merlin/NF2 inactivation in tumor biology |
| Q36507175 | Role of integrins in peripheral nerves and hereditary neuropathies |
| Q38552469 | Scaffolding during the cell cycle by A-kinase anchoring proteins. |
| Q30500623 | Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein |
| Q57189203 | Schwann cell proliferation as the cause of peripheral neuropathy in neurofibromatosis-2 |
| Q38180808 | Schwannomas and their pathogenesis |
| Q28298948 | Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c) |
| Q28204271 | Schwannomin isoform-1 interacts with syntenin via PDZ domains |
| Q30502106 | Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length |
| Q41037971 | Schwannomin: new insights into this member of the band 4.1 superfamily |
| Q48075368 | Screening for germ-line mutations in the NF2 gene |
| Q71131047 | Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas |
| Q35633077 | Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain |
| Q35789823 | Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction |
| Q71917074 | Sensorineural hearing loss in children |
| Q28283023 | Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression |
| Q92875221 | Somatic Mutations of lats2 Cause Peripheral Nerve Sheath Tumors in Zebrafish |
| Q35765036 | Somatic deletion of the 5' ends of both the COL4A5 and COL4A6 genes in a sporadic leiomyoma of the esophagus |
| Q72573384 | Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas |
| Q24323074 | Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2 |
| Q30495700 | Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study |
| Q35620822 | Spinal neurinomas: retrospective analysis and long-term outcome of 179 consecutively operated cases and review of the literature |
| Q35425868 | Spinal schwannomatosis in the absence of neurofibromatosis: A very rare condition. |
| Q36425527 | Stability of the tumor suppressor merlin depends on its ability to bind paxillin LD3 and associate with β1 integrin and actin at the plasma membrane |
| Q47145615 | Stereotactic radiosurgery does not appear to impact cochlear implant performance in patients with neurofibromatosis type II. |
| Q30977333 | Strong conservation of the human NF2 locus based on sequence comparison in five species. |
| Q27683013 | Structural Basis of the Binding of Merlin FERM Domain to the E3 Ubiquitin Ligase Substrate Adaptor DCAF1 |
| Q24682640 | Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization |
| Q27637088 | Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain |
| Q27690668 | Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function |
| Q27640373 | Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex |
| Q24598762 | Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain |
| Q27622801 | Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain |
| Q30431490 | Structure-function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein |
| Q30494561 | Submembranous junctional plaque proteins include potential tumor suppressor molecules |
| Q57042603 | Subtotal resection of cervical dumbbell schwannomas: radiographic predictors for surgical considerations |
| Q74549886 | Summary of ocular genetic disorders and inherited systemic conditions with eye findings |
| Q35633702 | Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1) |
| Q87916960 | Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation |
| Q48743328 | Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises |
| Q50021909 | Syndromic Hearing Loss: A Brief Review of Common Presentations and Genetics |
| Q80250082 | Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin |
| Q52726723 | Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. |
| Q24534317 | The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins |
| Q38189166 | The Angiomotins--from discovery to function |
| Q37796203 | The Diagnostic and Clinical Significance of Café-au-lait Macules |
| Q42771059 | The Drosophila lethal(2)giant larvae tumor suppressor protein forms homo-oligomers and is associated with nonmuscle myosin II heavy chain |
| Q42529926 | The Drosophila tumor suppressors Expanded and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling |
| Q38997320 | The Emerging Role of TRAF7 in Tumor Development |
| Q30487287 | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study |
| Q28284187 | The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane |
| Q24603986 | The Hippo Signaling Pathway in Development and Cancer |
| Q38083640 | The Hippo pathway: regulators and regulations |
| Q99555888 | The Importance of Early Genetic Diagnostics of Hearing Loss in Children |
| Q30429717 | The NF2 Tumor Suppressor, Merlin, Regulates Epidermal Development through the Establishment of a Junctional Polarity Complex |
| Q28363493 | The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44 |
| Q30606515 | The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway |
| Q35645574 | The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion |
| Q52731433 | The PP1 phosphatase flapwing regulates the activity of Merlin and Moesin in Drosophila. |
| Q47859501 | The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule |
| Q77752526 | The diagnosis and management of neurofibromatosis 2 in childhood |
| Q36415420 | The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene |
| Q38105599 | The expanding family of FERM proteins. |
| Q30428648 | The ezrin protein family: membrane-cytoskeleton interactions and disease associations |
| Q41225741 | The human chromosome 22-located genes and malignancies of the central nervous system |
| Q41017187 | The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas |
| Q35448670 | The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. |
| Q42812549 | The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity |
| Q40898736 | The molecular biology of ependymomas |
| Q30467803 | The molecular biology of vestibular schwannomas and its association with hearing loss: a review. |
| Q40554569 | The molecular genetics of vestibular schwannoma. |
| Q28306517 | The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis |
| Q28218786 | The motor protein kinesin-1 links neurofibromin and merlin in a common cellular pathway of neurofibromatosis |
| Q36194939 | The multiple functions of TRBP, at the hub of cell responses to viruses, stress, and cancer |
| Q41814702 | The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner |
| Q35842044 | The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases. |
| Q39677459 | The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells |
| Q46297988 | The ocular presentation of neurofibromatosis 2. |
| Q33756302 | The phacomatoses. |
| Q28354232 | The protein 4.1, ezrin, radixin, moesin (FERM) domain of Drosophila Coracle, a cytoplasmic component of the septate junction, provides functions essential for embryonic development and imaginal cell proliferation |
| Q33314158 | The role of Drosophila Merlin in spermatogenesis |
| Q42509945 | The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. |
| Q38172070 | The role of vascular endothelial growth factor and vascular stability in diseases of the ear. |
| Q34474913 | The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis |
| Q28586327 | The zebrafish band 4.1 member Mir is involved in cell movements associated with gastrulation |
| Q30418605 | Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. |
| Q37387020 | Three determinants in ezrin are responsible for cell extension activity |
| Q91107708 | Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms |
| Q24682018 | Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon |
| Q40170388 | Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. |
| Q30458767 | Treatment of vestibular schwannoma cells with ErbB inhibitors |
| Q58191844 | Tumor Suppressor Schwannomin/Merlin Is Critical for the Organization of Schwann Cell Contacts in Peripheral Nerves |
| Q41625163 | Tumor suppressor genes and human cancer |
| Q41118798 | Tumor suppressor genes and medulloblastoma |
| Q40568049 | Tumor suppressor genes and their roles in breast cancer |
| Q40568235 | Tumor suppressor genes in molecular medicine |
| Q33788736 | Tumor suppressor genes in ophthalmology |
| Q47948675 | Tumor suppressor genes: prospects for cancer therapies |
| Q34207916 | Tumorigenesis in neurofibromatosis: new insights and potential therapies |
| Q24298753 | Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase |
| Q38190591 | Tumors of the anterior skull base |
| Q26864763 | Tumors of the neural crest: Common themes in development and cancer |
| Q24321386 | Two independent domains of hDlg are sufficient for subcellular targeting: the PDZ1-2 conformational unit and an alternatively spliced domain |
| Q30502816 | Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease |
| Q50511661 | Unilateral acoustic neuroma in childhood. |
| Q42839207 | Universal absence of merlin, but not other ERM family members, in schwannomas. |
| Q48451937 | Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET. |
| Q34176631 | Using the neurofibromatosis tumor predisposition syndromes to understand normal nervous system development |
| Q44649526 | Vestibular Schwann cells are a distinct subpopulation of peripheral glia with specific sensitivity to growth factors and extracellular matrix components |
| Q35575942 | Voltage‐Gated ion currents of schwann cells in cell culture models of human neurofibromatosis |
| Q28272241 | VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation |
| Q64985718 | Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. |
| Q36737585 | YAPing Hippo Forecasts a New Target for Lung Cancer Prevention and Treatment |
| Q54563781 | [Neurofibromatoses]. |
| Q50455607 | [Neurofibromatosis type 2] |
| Q79938815 | [Phenotype-genotype study in 154 French NF2 mutation carriers] |
| Q81596238 | [Polyneuropathy associated with neurofibromatosis] |
| Q91910718 | miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells |
| Q30401833 | p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. |
Search more.